The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T cells to the airways
© Glaichenhaus and Julia; licensee BioMed Central Ltd. 2011
Published: 23 November 2011
The prevalence of asthma has steadily increased during the last decade, probably as the result of changes in the environment, including reduced microbial exposure during infancy. Accordingly, experimental studies have shown that deliberate infections with live pathogens prevent the development of allergic airway diseases in mice. Bacterial extracts are currently used in children suffering from repeated upper respiratory tract infections. In this study, we have investigated whether bacterial extracts, commercially available as Broncho-Vaxom (BV), could prevent allergic airway disease in mice.
Oral treatment with BV suppressed airway inflammation through IL-10-dependent and MyD88-dependent mechanisms and induced the conversion of FoxP3-negative T cells into FoxP3-positive regulatory T cells. Furthermore, CD4-positive T cells purified from the trachea of BV-treated mice conferred protection against airway inflammation when adoptively transferred into sensitized mice.
Treatment with BV could possibly be a safe and efficient strategy to prevent the development of allergic disease in children.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.